Paul Lisi, DO
Pulmonary Disease · Cudahy, WINPI 1194943399
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,000 of the $12,385 with a category attached, or 80.7%. GSK accounts for 69.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $9,925 and has fallen 99.2% since, to $79 in 2025. Among pulmonary disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $190.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$9K
- Viiv Healthcare Company$2K
- AstraZeneca$2K
- Philips North America LLC$244
- Boehringer Ingelheim$142
- Mylan Specialty L.p.$57
- plus $137 from 6 others
Across 34 payments — averaging $12,071 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$367K
- Boehringer Ingelheim$43K
What the payments were for
- Consulting fees$1,34811%
- Speaking & faculty fees$10,00081%
- Food & beverage$1,0068%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $8,656 |
| Viiv Healthcare Company | 1 | $1,600 |
| AstraZeneca | 7 | $1,549 |
| Philips North America LLC | 27 | $244 |
| Boehringer Ingelheim | 3 | $142 |
| Mylan Specialty L.p. | 3 | $57 |
| Genentech USA, Inc. | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Amgen | 1 | $21 |
| Insmed, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$8,525
How this compares
$12,385 in reported general payments places this provider in the 90th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 477 | $408,274 |
| OfevNintedanib Esylate | 21 | $282,731 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 226 | $129,446 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 125 | $95,842 |
| Breo ElliptaFluticasone/Vilanterol | 134 | $69,938 |
| Dupixent PenDupilumab | 13 | $57,382 |
| Spiriva HandihalerTiotropium Bromide | 43 | $39,837 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 46 | $32,444 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $31,114 |
| SymbicortBudesonide/Formoterol Fumarate | 80 | $24,911 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 128 | $19,911 |
| Spiriva RespimatTiotropium Bromide | 18 | $11,692 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $10,769 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 325 | $10,658 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $7,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $8,656 | $619,925865 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat, Spiriva Respimat | $142 | $357,981122 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,549 | $120,753205 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Cudahy
- Mathew MathaiCudahy$28K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.